You're an idiot. No one told you the uplist would take it to $240 a share you dingbat. It simply makes it POSSIBLE for most investors to buy the shares, they still have to know about it and think it's a good opportunity.
In the long run, this will be an extremely valuable company. Not sure when those milestones will ALL hit, for some, the time frame is quite optimistic there, but I like your optimism, and I do think the technology will reshape medicine, and in that, you have another large pharma evolving here, if it's not bought out first, by another company. The market is a bit slow in understanding, as this should be much more valuable at this stage, given that it's not a drug, but involves replacing the actual tissue that is degenerating, and given the amazing results which, while they don't pass FDA approval requirements yet, are statistically enough for most investors as to start to qualify for a very very strong, long-term, obvious play. In my life's experience, the likelihood that these first 17 are different than the next 38 by a HUGE factor would be extremely anomalous, across so many test centers, doctors and patients, as well as after having it peer reviewed. If they got another 75% of the results they got here, and that would be shockingly less than what I'd expect, or even 50% of the results here on the next 50, given 17 out of 18 had their disease stopped and no safety issues for the cells, it's an incredible blockbuster. That Wall Street and ordinary investors haven't yet realized it, just makes it an incredible opportunity and value, long-term for anyone with half of a brain and paying attention. Things can always go wrong, that's the nature of these things, but the probabilities here are quite unlikely at this stage, in my view, given what has been clearly demonstrated, time and time again, in different circumstances, and from animals to humans. This will, IMHO, be huge, without a doubt. And RPE cells are just the beginning.
Old news, this is the registration of the Lincoln funding that they agreed to last Fall. It's just the registration rights being updated. That's why it's an "AMENDMENT". Not a new issuance in the most obvious sense of the word. An update of their last filing.
You're so silly to think I am FP. Different posters, from different parts of the world, with entirely different life's experiences.
You are so right FP and not really my concern either, just trying to explain it for the newbies coming upon this board and trying to understand all the negativity and noise. It's just traders, manipulating sentiment so that they can complete their trading cycles, like insects that hatch, breed, lay eggs and die . . . and then repeat the cycle.
Like you, I'm a long, and I don't care to see others do anything particularly, but what they want, with their dollars. But it's good that they understand a little, what gives . . . here, with this ridiculous tempest and noise, here and elsewhere. Also, it's not a stock to invest in, because of the balance sheet, it's a start-up, with no revenues, just possible pending big deals that could happen at any time because of technology alone. So you have to evaluate that all by yourself, brokerage standard recomendations simply are not in depth enough or careful enough to provide a fair understanding of a company with prospects like this one, or its real virtues or real challenges.
Enjoy Maui FP and I wish you the best FP. The best to all the longs!
The volatility junkies that treat this stock, like their personal ATM, spend their time here on this bulletin board because it reaches people who are easily influenced by fear. People don't buy easily, but they can be frightened into action, to selling, easily.
These persons sold on the day the stock uplisted, now they must drive the stupid people, who try to trade this and don't know what they are doing, out of the stock with fear, and then they will get back in again around the obvious bottom, at the lowest price possible, and ride it up again, rinse and repeat.
Cowen underwrites many major biotechs, along with Jeffries and middle size, but growing rapidly, investment banks of its size and nature.
If you needed to look them up, you clearly demonstrated a lack of industry and market knowledge.
Oh, that's right, it's an ADULT stem cell company. . . it's too bad those treatments are so difficult to make work and are a therapy, so are hard to turn into a scalable business. It must be tough.
Both Cowen and Jeffries are different investment banking firms. Apparently, given that the uplist is to NASDAQ Global Markets, without the offering, and was only to NASDAQ Capital Markets with the offering, which is only for small caps, they did not need the offering. That seems to suggest something good was the cause of the withdrawn offering, in my humble opinion, but of course, one can only speculate given the filing docs and the qualifiation/requirements for the two NASDAQ markets. This has been discussed on other boards. This is really not the best place for thoughtful information.
In 2011, that was at $8.00 no? Just a little while ago . . . and you're posting here because?
Very tiny market cap on that stock. Easy to move that up an down withou much money. Perfect for you trader types.
I don't know about Jeffries, did you have news on that front? Excited to see good things coming to pass, as most of us longs knew they would, given the circumstances here.
The issue for these bashers is they take advantage of short-term investors, as traders who know these things fluctuate. I'm sure they are more informed than they suggest by their very bad posts.
I can't believe this board is so filled with nonsense every day. The coming events should help to prove the nonsense that has been the state for this board for many years now.
It's a long termer Keep. Apparently you don't know anything about investing in start-ups. or you do, and you are a professional basher, which I think is the more likely result.
1. Uplist on Thursday, per SEC filing last evening;
2. New Patent for MSC cells PUBLISHED today;
3. They are uplisting to the NASDAQ Global Markets, a more stringent uplisting than just as a small cap, so it seems, people are wondering, why this might be true . . . but as of yet, we don't know. NASDAQ Global Markets is for mid-cap.
We are awaiting start of Phase II injections, for SMD, and for publication of additional results from Korea, I believe. We'll see what more could happen. And the CEO is speaking, per the press release, next week.